Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
ACS Applied Materials & Interfaces|May 25, 2019
Stretchable Polymer Gate Dielectric by Ultraviolet-Assisted Hafnium Oxide Doping at Low Temperature for High-Performance Indium Gallium Tin Oxide TransistorsJae Seok Hur, Jeong Oh Kim, Hyeon A Kim, et al.
Anticancer Research|October 1, 2021
Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS MutationsKyoung-Hwa Son, Min-Young Kim, Jung-Young Shin, et al.
BMC Cancer|August 14, 2010
LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cellsJung-Young Shin, Jeong-Oh Kim, Suk Kyeong Lee, et al.
Cancer Research and Treatment|October 16, 2010
Influence of reduced folate carrier and dihydrofolate reductase genes on methotrexate-induced cytotoxicitySeong-Ae Yoon, Jung Ran Choi, Jeong-Oh Kim, et al.
American Journal of Cancer Research|March 10, 2023
FOXA2 and STAT5A regulate oncogenic activity of KIF5B-RET fusionMi-Ran Lee, Jung-Young Shin, Min-Young Kim, et al.
Cancer Biology & Therapy|June 25, 2013
A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRASXiang-Hua Zhang, Ying Cheng, Jung-Young Shin, et al.
Cancers|December 3, 2020
A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for EGFR Mutations in Plasma from Non-Small Cell Lung Cancer PatientsJung-Young Shin, Jeong-Oh Kim, Mi-Ran Lee, et al.
BMC Cancer|November 4, 2020
Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinomaMin-Young Kim, Jung-Young Shin, Jeong-Oh Kim, et al.
Cancer Letters|March 22, 2012
Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutationsXiang-Hua Zhang, Jung-Young Shin, Jeong-Oh Kim, et al.
Blood Research|November 16, 2019
Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpuraJisu Oh, Doyeun Oh, Seon Ju Lee, et al.
Pageof 3